Skip to main content
SpringerLink
Log in

Ritonavir

  • New Drug Profile
  • Published:
Drugs Aims and scope Submit manuscript

Summary

▴ Ritonavir is a protease inhibitor with an HIV-1 resistance profile similar to that of indinavir, but different from that of saquinavir.

▴ Ritonavir has good oral bioavailability, and may increase the bioavailability of other protease inhibitors including saquinavir, nelfinavir, indinavir and VX-478.

▴ Clinically significant drug interactions have been predicted between ritonavir and a range of medications.

▴ In patients with HIV-1 infection, ritonavir markedly reduced viral load within 2 weeks of treatment onset and also increased CD4+ cell counts.

▴ In a large placebo-controlled trial in patients with advanced HIV infection, the addition of ritonavir to existing therapy reduced the risk of mortality by 43% and clinical progression by 56% after 6.1 months.

▴ Triple therapy with ritonavir plus zidovudine, in combination with lamivudine or zalcitabine, reduced HIV viraemia to below detectable levels in most patients with acute, and some patients with advanced HIV infection in 2 small trials.

▴ Early results suggest combination therapy with ritonavir and saquinavir increases CD4+ cell counts and decreases HIV RNA levels in patients with previously untreated HIV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12

    Article  PubMed  CAS  Google Scholar 

  2. Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995 Mar 28; 92: 2484–8

    Article  PubMed  CAS  Google Scholar 

  3. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments]. Nature 1995 Jan 12; 373: 123–6

    Article  PubMed  CAS  Google Scholar 

  4. Kelleher AD, Carr A, Zaunders J. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996 Feb; 173: 321–9

    Article  PubMed  CAS  Google Scholar 

  5. Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Natur Med 1996; 2(7): 760–6

    Article  CAS  Google Scholar 

  6. Eastman SP, Reed K, Boyer E, et al. Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisation of genotypic mutations at codon 82 of the HIV-1 protease gene [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 90

    Google Scholar 

  7. Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995 Feb; 69: 701–6

    PubMed  CAS  Google Scholar 

  8. Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibiters [letter]. Nature 1995 Apr 6; 374: 569–71

    Article  PubMed  CAS  Google Scholar 

  9. Hsu A, Granneman R, Rynkiewicz K, et al. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses [abstract]. Pharm Res 1994 Oct; 11 Suppl.: 400

    Google Scholar 

  10. Danner SA, Carr A, Leonard JM. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995 Dec 7; 333: 1528–33

    Article  PubMed  CAS  Google Scholar 

  11. Norvir™ (ritonavir capsules) (ritonavir oral solution). Prescribing Information. Abbott Laboratories, Chicago, Illinois, USA

  12. Data on file. Abbott Laboratories, Chicago, Illinois, USA. 1996

  13. Kumar GN, Rodrigues D, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277(1): 423–31

    PubMed  CAS  Google Scholar 

  14. Quellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers [abstract]. XI International Conference on AIDS; 1996 Jul 7; Vancouver

    Google Scholar 

  15. Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  16. Kumar GN, Grabowski B, Lee R, et al. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab Dispos 1996; 24(5): 615–7

    PubMed  CAS  Google Scholar 

  17. Cato A, Cavanaugh JH, Shi A, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver, 89

    Google Scholar 

  18. Altarac D, Koll BS. Management of the patient with human immunodeficiency virus disease. In: Rakel RE, editor. Conn’s Current Therapy. 48th ed. Philadelphia: WB Saunders Company, 1996: 47–66

    Google Scholar 

  19. Oullet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir (R) and clarithromycin (C). Clin Pharmacol Ther 1996; 59(2): 143

    Article  Google Scholar 

  20. Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 79

    Google Scholar 

  21. Hsu A, Granneman GR, Sun E, el al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  22. Cato A, Qian J, Carothers L, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine [abstract]. Clin Pharmacol Ther 1996; 59(2): 144

    Article  Google Scholar 

  23. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstract]. 35th International Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17; 211

    Google Scholar 

  24. Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [abstract]. 35th International Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; 211

    Google Scholar 

  25. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995 Dec 7; 333: 1534–9

    PubMed  CAS  Google Scholar 

  26. Mueller BU, Zuckerman J, Nelson Jr. RP, et al. A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection [abstract]. XI International Conference on AIDS 2: 1996 Jul 7; Vancouver, 31

    Google Scholar 

  27. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 162

    Google Scholar 

  28. Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  29. Heath-Chiozzi M, Leonard J, Henry D, et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency [abstract]. Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28; Washington DC.

    Google Scholar 

  30. Nabulsi A, Revicki D, Conway D, et al. The use of EuroQol preference scale in AIDS. Results from two clinical trials [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  31. Abbott Novir for HIV reduces death risk 40%, reduces disease progression risk 55% in advanced HIV; FDA approves ritonavir March 1 in record 72 days. FDC Rep Pink Sheet 1996 Mar 4: 7-8

  32. US NDA for Abbott’s ritonavir. Scrip 1996Jan 2/5; 2090/91: 23

  33. Swift US approval for Abbott’s Norvir. Scrip 1996 Mar 8; 2109: 17

  34. Mathez D, De Truchis P, Gorin I, et al. A triple combination of ritonavir+AZT+DDC as a first line treatment of patients with AIDS: update [poster]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  35. Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1 [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  36. Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver

    Google Scholar 

  37. FDA. HIV protease inhibitors and patients with hemophilia. Letter to Healthcare Providers. FDA: 1996 Jul 17

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, Private Bag 65901, 41 Centorian Drive, Mairangi Bay, Auckland 10, New Zealand

    Andrew P. Lea & Diana Faulds

Authors
  1. Andrew P. Lea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Diana Faulds
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lea, A.P., Faulds, D. Ritonavir. Drugs 52, 541–546 (1996). https://doi.org/10.2165/00003495-199652040-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199652040-00007

Keywords

Search

Navigation